Business
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026.
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time","length":80,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026.","length":384,"tagName":"p"},{"type":"image","alt":"Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":115,"url":"https://media.zenfs.com/en/prnewswire.com/8a1e3a48ba1eed38d0965ff99386679c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZacgsMHcTH4bVMkIFotjRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIwMw--/https://media.zenfs.com/en/prnewswire.com/8a1e3a48ba1eed38d0965ff99386679c","width":400,"height":115}},"href":"https://mma.prnewswire.com/media/273590/viking_9_15_logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, April 29, 2026. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until May 6, 2026, by dialing (855) 669-9658 from the U.S. and Canada, or (412) 317-0088 and entering conference replay code #2410242. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.","length":835,"tagName":"p"},{"type":"text","content":"About Viking Therapeutics, Inc.","length":31,"tagName":"p"},{"type":"text","content":"Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in...